Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

SML0245

Sigma-Aldrich

Candesartan cilexetil

≥98% (HPLC)

Sinonimo/i:

2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, TCV 116, TCY 116

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C33H34N6O6
Numero CAS:
145040-37-5
Peso molecolare:
610.66
Numero MDL:
MFCD00871371
Codice UNSPSC:
12352200
ID PubChem:
329825255
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: ≥15 mg/mL

Ideatore

Takeda

Temperatura di conservazione

2-8°C

Stringa SMILE

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)
GHOSNRCGJFBJIB-UHFFFAOYSA-N

Informazioni sul gene

human ... AGTR1(185)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

Caratteristiche e vantaggi

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Takeda. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H360D,H373

Classi di pericolo

Repr. 1B - STOT RE 2 Oral

Organi bersaglio

Kidney,Blood

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
113M4707V
072M4749V
012M4714V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Candesartan cilexetil British Pharmacopoeia (BP) Reference Standard

BP1248

Candesartan cilexetil

Olmesartan ≥98% (HPLC)

Sigma-Aldrich

SML1394

Olmesartan

USP

USP

1087814

Candesartan cilexetil Related Compound A

Candesartan Cilexetil Impurity E Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2036

Candesartan Cilexetil Impurity E

Azilsartan ≥98% (HPLC)

Sigma-Aldrich

SML0432

Azilsartan

Candesartan cilexetil for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001389

Candesartan cilexetil for system suitability

Olmesartan medoxomil ≥98% (HPLC)

Sigma-Aldrich

SML1391

Olmesartan medoxomil

Telmisartan ≥98% (HPLC), solid

Sigma-Aldrich

T8949

Telmisartan

Geranylgeranylacetone

Sigma-Aldrich

G5048

Geranylgeranylacetone

Ji-Young Jeon et al.
Drug development and industrial pharmacy, 39(9), 1296-1299 (2012-10-04)
Candesartan is a long-acting and selective nonpeptide AT1 subtype angiotensin II receptor antagonist. The aim of this study was to compare the pharmacokinetics and to evaluate the bioequivalence of two candesartan cilexetil 16 mg formulations. Forty healthy volunteers were randomly assigned
Po-Yin Chu et al.
PloS one, 10(7), e0133616-e0133616 (2015-07-28)
Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiovascular fibrosis. We sought to
Greg L Plosker et al.
PharmacoEconomics, 24(12), 1249-1272 (2006-11-30)
The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis
Gerd Bönner et al.
Current medical research and opinion, 21(6), 935-940 (2005-06-23)
Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. This short review summarises results of clinical studies focusing on the duration of action of candesartan cilexetil. Results of previous clinical studies indicate that candesartan
G Mancia et al.
Journal of human hypertension, 14 Suppl 2, S3-10 (2000-11-22)
The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.